From Casablanca to the Front Line of Cancer Drug Development
Biotech·November 20, 2026
Some of the most complex medicines available today are not chemical compounds at all. They are made from living cells or organisms, a class of products known as bio-pharmaceuticals. Dr Bahija Jallal, chief executive of the biotech company Immunocore, has built much of her career around this field, and her route into it started in Casablanca, Morocco.
In a recent episode of the BBC Radio 4 programme The Life Scientific, presenter Professor Jim Al-Khalili spoke with Jallal about how she got there. She described herself as someone who has usually been ahead of the curve. When she began working in oncology, the study of cancer, the standard treatment was chemotherapy, which attacks every cell in the affected area, healthy ones included. Her early research asked whether certain therapies could focus on cancerous cells alone and move away from what she called the sledgehammer of conventional chemotherapy.
That line of inquiry was an early step toward what came to be known as targeted cancer therapies. It set her on a career devoted to developing innovative drugs that could improve the lives of patients. She credits her results to a deep understanding of the science and a firm commitment to getting treatments to the people who need them.
For readers following the drug industry, the interview offers a useful look at how the field has moved. Treatments built from living systems are harder to design and manufacture than traditional pills, yet they can target disease with a precision that older approaches could not match. Jallal's story shows how that shift depended on researchers who were willing to question the established methods of their time.
Reporting based on an external source.